【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Arcfra Partner Day 2024 Successfully Held in Seoul
SEOUL, South Korea, Dec. 10, 2024 /PRNewswire/ -- Arcfra Pte. Ltd. (hereinafter referred to as "Arcfra," arcfra.com), a leading innovator in cloud infrastructure and full-stack solutions, hosted its first event for Korean partners on November 27th...
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 10, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies...
Adoption of an Exclusive Human Milk Diet Reduces Malnutrition Rates Among Vulnerable Premature Infants in Sydney Hospital
Preliminary Data From Observational Study Presented at Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference ADELAIDE, Australia, Dec. 10, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital...
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263...
SR_A HUBLOT 3.0 IN PARTNERSHIP WITH DR SAMUEL ROSS MBE
Faithful to Hublot's 'Art of Fusion', the brilliant artist and designer Samuel Ross takes his creativity to new heights through considered and accomplished work involving a variety of materials and colours. This new edition of the Hublot Big Bang...
PEARSON ENGLISH LANGUAGE TEACHING AWARD WINNER ONE OF 12,000 TEACHERS HELPING INDONESIAN GOVERNMENT LIFT ENGLISH PROFICIENCY
JAKARTA, Indonesia, Dec. 4, 2024 /PRNewswire/ -- Pearson (LON: PSON), the world's leading learning company, today announced Ulfa Rafiqha has achieved a Silver in the Pearson English Language Teacher Awards. She is one of 12,000 teachers who just...
Global Times: 10 years on: President Xi's book on governance has sweeping global impact
BEIJING, Dec. 2, 2024 /PRNewswire/ -- On November 15, in Lima, Peru, during the sidelines of the 31st APEC Economic Leaders' Meeting, Chilean President Gabriel Boric presented Chinese President Xi Jinping with the fourth volume of the collection Xi...